Alitalo K - Search Results

1

Characterization of ANGPT2 mutations associated with primary lymphedema.

Leppänen VM, Brouillard P, Korhonen EA, Sipilä T, Jha SK, Revencu N, Labarque V, Fastré E, Schlögel M, Ravoet M, Singer A, Luzzatto C, Angelone D, Crichiutti G, D'Elia A, Kuurne J, Elamaa H, Koh GY, Saharinen P, Vikkula M, Alitalo K. Leppänen VM, et al. Among authors: alitalo k. Sci Transl Med. 2020 Sep 9;12(560):eaax8013. doi: 10.1126/scitranslmed.aax8013. Sci Transl Med. 2020. PMID: 32908006

2

The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cdelta.

Saharinen P, Ekman N, Sarvas K, Parker P, Alitalo K, Silvennoinen O. Saharinen P, et al. Among authors: alitalo k. Blood. 1997 Dec 1;90(11):4341-53. Blood. 1997. PMID: 9373245 Free article.

3

Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response.

Korpelainen EI, Kärkkäinen M, Gunji Y, Vikkula M, Alitalo K. Korpelainen EI, et al. Among authors: alitalo k. Oncogene. 1999 Jan 7;18(1):1-8. doi: 10.1038/sj.onc.1202288. Oncogene. 1999. PMID: 9926914

4

Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema.

Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. Karkkainen MJ, et al. Among authors: alitalo k. Nat Genet. 2000 Jun;25(2):153-9. doi: 10.1038/75997. Nat Genet. 2000. PMID: 10835628

5

Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase.

Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. Irrthum A, et al. Among authors: alitalo k. Am J Hum Genet. 2000 Aug;67(2):295-301. doi: 10.1086/303019. Epub 2000 Jun 9. Am J Hum Genet. 2000. PMID: 10856194 Free PMC article.

6

The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner.

Ekman N, Arighi E, Rajantie I, Saharinen P, Ristimäki A, Silvennoinen O, Alitalo K. Ekman N, et al. Among authors: alitalo k. Oncogene. 2000 Aug 24;19(36):4151-8. doi: 10.1038/sj.onc.1203763. Oncogene. 2000. PMID: 10962576

7

Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.

Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, Ylä-Herttuala S, Alitalo K. Mäkinen T, et al. Among authors: alitalo k. Nat Med. 2001 Feb;7(2):199-205. doi: 10.1038/84651. Nat Med. 2001. PMID: 11175851

8

A model for gene therapy of human hereditary lymphedema.

Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, Bueler H, Eichmann A, Kauppinen R, Kettunen MI, Yla-Herttuala S, Finegold DN, Ferrell RE, Alitalo K. Karkkainen MJ, et al. Among authors: alitalo k. Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12677-82. doi: 10.1073/pnas.221449198. Epub 2001 Oct 9. Proc Natl Acad Sci U S A. 2001. PMID: 11592985 Free PMC article.

9

Insights into the molecular pathogenesis and targeted treatment of lymphedema.

Saaristo A, Karkkainen MJ, Alitalo K. Saaristo A, et al. Among authors: alitalo k. Ann N Y Acad Sci. 2002 Dec;979:94-110. doi: 10.1111/j.1749-6632.2002.tb04871.x. Ann N Y Acad Sci. 2002. PMID: 12543720 Review.

10

Double target for tumor mass destruction.

Saharinen P, Alitalo K. Saharinen P, et al. Among authors: alitalo k. J Clin Invest. 2003 May;111(9):1277-80. doi: 10.1172/JCI18539. J Clin Invest. 2003. PMID: 12727916 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

719 results

Search Page